VOR Stock Overview
Operates as a clinical-stage cell and genome engineering company.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Vor Biopharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.09 |
52 Week High | US$3.14 |
52 Week Low | US$0.70 |
Beta | -0.34 |
11 Month Change | 32.93% |
3 Month Change | -13.49% |
1 Year Change | -57.59% |
33 Year Change | -93.04% |
5 Year Change | n/a |
Change since IPO | -97.09% |
Recent News & Updates
Recent updates
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely
Sep 10We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 24Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Dec 05Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?
Aug 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
May 05Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?
Mar 13We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Oct 19Vor Bio appoints Eyal C. Attar as chief medical officer
Oct 12Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?
Jun 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Mar 05Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Aug 30Vor Biopharma: Targeted Therapies For Transplants
Jun 30We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 10Vor Biopharma EPS misses by $0.03
May 06Shareholder Returns
VOR | US Biotechs | US Market | |
---|---|---|---|
7D | 30.8% | -1.9% | -3.4% |
1Y | -57.6% | 13.9% | 19.6% |
Return vs Industry: VOR underperformed the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: VOR underperformed the US Market which returned 19.6% over the past year.
Price Volatility
VOR volatility | |
---|---|
VOR Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VOR's share price has been volatile over the past 3 months.
Volatility Over Time: VOR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 168 | Robert Ang | www.vorbio.com |
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML.
Vor Biopharma Inc. Fundamentals Summary
VOR fundamental statistics | |
---|---|
Market cap | US$74.55m |
Earnings (TTM) | -US$118.09m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs VOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VOR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$118.09m |
Earnings | -US$118.09m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.73 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did VOR perform over the long term?
See historical performance and comparison